SGAM
AMAG

Smith Group Asset Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Smith Group Asset Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-969
Closed -$19K – 461
2014
Q1 		$19K Sell
969
-53,881
-98% -$1.14M ﹤0.01% 298
2013
Q4 		$1.33M Sell
54,850
-88
-0.2% -$2.07K 0.05% 172
2013
Q3 		$1.18M Sell
54,938
-5,690
-9% -$134K 0.05% 168
2013
Q2 		$1.35M Buy
+60,628
New +$1.34M 0.06% 173

Other funds holding AMAG

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Smith Group Asset Management's AMAG Position: Q2 2014 in Review

Smith Group Asset Management sold out of AMAG Pharmaceuticals (AMAG) in Q2 2014, closing a stake of 969 shares — an estimated $19K sold.

Smith Group Asset Management first reported a position in AMAG in Q2 2013 and held it in 4 quarters. The position peaked at $1.35M in Q2 2013. 100 funds tracked by Wall St. Rank hold AMAG as of Q2 2014.

  • Smith Group Asset Management reported no remaining AMAG Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Smith Group Asset Management sold 969 AMAG Pharmaceuticals shares in Q2 2014, an estimated $19K.
  • Smith Group Asset Management first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Smith Group Asset Management's AMAG Pharmaceuticals position peaked at $1.35M in Q2 2013.
  • 100 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2014.

Based on Smith Group Asset Management's 13F filing for Q2 2014, filed 23 Jul 2014.